logo
Twitter
Discord
Email
logo
Clover Health Investments, Corp.

Clover Health Investments, Corp.

NASDAQ•CLOV
CEO: Mr. Vivek Garipalli
Sector: Healthcare
Industry: Medical - Healthcare Plans
Listing Date: 2020-06-12
Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.
Contact Information
3401 Mallory Lane, Suite 210, Franklin, TN, 37067, United States
201-432-2133
www.cloverhealth.com/en
Market Cap
$1.33B
P/E (TTM)
-22.7
0
Dividend Yield
--
52W High
$4.87
52W Low
$2.12
52W Range
17%
Rank66Top 89.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2024

Financial Dashboard

Q3 2025 Data

Revenue

$496.65M+50.05%
4-Quarter Trend

EPS

-$0.05+154.01%
4-Quarter Trend

FCF

$11.41M-76.99%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Premium Revenue Growth Net premiums earned reached $1.41B for nine months, increasing 38.6% driven by member growth.
Membership Base Expansion Average members grew approximately 32% over the nine months period, supporting revenue scale and data insights.
Operating Expense Leverage Adjusted SG&A as percentage of total revenues improved to 16.5% from 20.2% last year.
Cash Flow from Investing Investing activities provided $39.1M net cash, mainly from $139.5M in investment sales and maturities.

Risk Factors

Medical Claims Cost Inflation Net medical claims incurred rose 51.3% to $1.15B, outpacing net premium revenue growth rate.
CMS Star Rating Decrease PPO Medicare Advantage plans rating decreased to 3.5 Stars for 2026, impacting future payment year revenue.
Stock-Based Compensation Expense Total stock-based compensation recognized was $78.7M for nine months, contributing to net loss worsening.
Continued Net Loss Net loss from continuing operations totaled $(36.2M) for nine months, worsening by 49.0% versus prior period.

Outlook

Counterpart Health SaaS Growth Expanding Counterpart Health SaaS offering to external payors leverages existing AI platform for new revenue streams.
Clover Assistant Adoption Focus Focus remains on increasing adoption of Clover Assistant technology to manage medical loss ratios effectively.
Liquidity Sufficiency Confirmed Management expects current cash, investments, and projected cash flows sufficient for next twelve months obligations.
Future Accounting Standards Company currently evaluating impacts of several new FASB ASUs effective in future fiscal periods.

Peer Comparison

Revenue (TTM)

Teladoc Health, Inc.TDOC
$2.53B
-2.4%
Pediatrix Medical Group, Inc.MD
$1.92B
-4.2%
Clover Health Investments, Corp.CLOV
$1.77B
+14.8%

Gross Margin (Latest Quarter)

Phreesia, Inc.PHR
102.6%
+34.9pp
BioCryst Pharmaceuticals, Inc.BCRX
98.6%
+1.4pp
GoodRx Holdings, Inc.GDRX
93.2%
-0.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TXG$1.97B-26.3-10.3%8.5%
MD$1.86B11.319.8%29.2%
AZTA$1.58B-26.6-3.5%2.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
13.8%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 26, 2026
|
EPS:-$0.05
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 7, 2025|
    Revenue: $496.65M+50.1%
    |
    EPS: $-0.05+154.0%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $477.62M+34.1%
    |
    EPS: $-0.02-308.0%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 9, 2025|
    Revenue: $462.33M+33.3%
    |
    EPS: $-0.00-93.5%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 3, 2025|
    Revenue: $1.37B+8.8%
    |
    EPS: $-0.09+80.5%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 8, 2024|
    Revenue: $330.99M+8.2%
    |
    EPS: $-0.02-79.2%
    Meet

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $356.26M+11.3%
    |
    EPS: $0.01-116.7%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $346.92M+7.7%
    |
    EPS: $-0.04-73.3%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 14, 2024|
    Revenue: $1.26B+15.0%
    |
    EPS: $-0.45+36.6%
    Miss